Meeting
2023 ASCO Annual Meeting
Alliance A022101: A pragmatic, randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: Evaluating Radiation, Ablation, and Surgery (ERASur).
Authors
Kathryn Hitchcock
University of Florida, Gainesville, FL
Kathryn Hitchcock , Paul Bernard Romesser , Qian Shi , Jesse G. Dixon , Sepideh Gholami , Sarah B. White , Christina Wu , Christopher C. Goulet , Kyung-Wook Jee , Chadwick L. Wright , Rona Yaeger , Ardaman Shergill , Theodore S. Hong , Thomas J. George , Eileen Mary O'Reilly , Jeffrey A. Meyerhardt , Eric David Miller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT05673148
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3629)
DOI
10.1200/JCO.2023.41.16_suppl.TPS3629
Abstract #
TPS3629
Poster Bd #
326b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).
First Author: Raquibul Hannan
Poster
2023 ASCO Annual Meeting
Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG).
First Author: Miriam Koopman
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for unresectable locally advanced pancreatic cancer (TIGeR-PaC): A randomized phase 3 multicenter study.
First Author: Michael J. Pishvaian
Poster
2021 ASCO Annual Meeting
Resectability, conversion and resections rates, and outcomes in RAS&BRAF wildtype (wt), RAS mutant (mt) and BRAFmt metastatic colorectal cancer (mCRC) subgroups in the prospective Finnish RAXO-study.
First Author: Pia J. Osterlund